LEARN ABOUT IDENTIFYING THYROID EYE DISEASE (TED)

Spotting TED and treating early can benefit patients and may reduce the impact of the disease, helping avoid potentially permanent eye damage

TED is not a “watch and wait” disease—delaying diagnosis can potentially threaten patients’ vision and impact patients’ quality of life^1-4

TED is a progressive autoimmune disease with debilitating visible and nonvisible signs and symptoms^1,5-7
As the disease progresses, patients may notice worsening or additional symptoms that can create an ever-increasing burden of disease⁸
It can take some patients anywhere from 2 to nearly 5 years to get a TED diagnosis⁹

EARLY DIAGNOSIS AND TREATMENT OF TED IS IMPORTANT AS DAMAGE OFTEN STARTS BEFORE VISIBLE SIGNS APPEAR

The TED mnemonic tool below breaks down a differential diagnosis in 4 easy-to-remember steps.

TED can have a significant impact on a patient’s emotional well-being, making them feel self-conscious^8,10
If you suspect a patient has TED, it’s important to ask how they feel about themselves

TED can cause a wide range of ocular symptoms, including visible and nonvisible signs and symptoms^6,7
Screen your patients for all ocular symptoms of TED

TED patients often have a history of autoimmune thyroid conditions, like Graves’ disease³
If your patient has a thyroid disorder, screen for TED

Download the Patient Intake Form to help evaluate suspected TED patients or to assess the full impact of TED on their quality of life.

If you SPOT 2 or more of these signs or symptoms, download the mnemonic tool and consider TED as part of your differential diagnosis.

Next Page >

Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125.
Bothun ED, Scheurer RA, Harrison AR, Lee MS. Update on Thyroid Eye Disease and management. Clin Ophthalmol. 2009;3:543-551.
Burch HB, Perros P, Bednarczuk T, et al. Management of Thyroid Eye Disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022;32(12):1-32.
Wang Y, Sharma A, Padnick-Silver L, et al. Physician-perceived impact of thyroid eye disease on patient quality of life in the United States. Ophthalmol Ther. 2021;10(1):75-87.
Wang Y, Patel A, Douglas RS. Thyroid Eye Disease: how a novel therapy may change the treatment paradigm. Ther Clin Risk Manag. 2019;15:1305-1318.
Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726-738.
Thyroid Eye Disease. National Organization for Rare Disorders. 2020. Accessed December 8, 2022. https://rarediseases.org/rare-diseases/thyroid-eye-disease
Cockerham KP, Padnick-Silver L, Stuertz N, Francis-Sedlak L, Holt RJ. Quality of life in patients with chronic Thyroid Eye Disease in the United States. Ophthalmol Ther. 2021;10:975-987.
Data on File. Horizon, April 2020.
Smith TJ, Hegedüs L, Lesser I, Perros P, Dorris K, Kinrade M, Troy-Ott P, Wuerth L, Nori M. How patients experience thyroid eye disease. Front Endocrinol (Lausanne). 2023 Nov 9;14:1283374.

Receive the latest news and updates about Thyroid Eye Disease (TED).

expand_less expand_more